Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
thyroid neoplasms/unwohlsein und ermüdung
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 111 Ergebnisse
Perception of treatment burden, psychological distress, and fatigue in thyroid cancer patients and their partners - effects of gender, role, and time since diagnosis.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVE
The aim of this study was to examine diagnosis and treatment burden as well as psychological distress (anxiety and depression) and fatigue in thyroid cancer patients and their partners, focusing on the effects of gender, role, and time since diagnosis.
METHODS
Seventy-one patients
Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
The aims of this study were (i) to obtain insight into the prevalence of fatigue among short- and long-term thyroid cancer (TC) survivors, by comparing a sample of TC survivors with an age- and sex-matched normative population, and (ii) to investigate which demographic, clinical, and
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVE
This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit in advanced medullary thyroid cancer
Motesanib diphosphate in progressive differentiated thyroid cancer.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived
A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC). DNA microarray analysis has shown platelet-dervived growth factor receptor (PDGFR) overexpression in ATC relative to well-differentiated thyroid cancer. In p53-mutated/deficient ATC cell lines, cABL
Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Lenvatinib mesylate (E7080; 4-[3-chloro-4-(N'-cyclopropylureido) phenoxy] 7-methoxyquinoline-6-carboxamide mesylate) is an oral molecule that inhibits multiple tyrosine kinase receptors such as VEGF-R-1-3, FGF-R-1-4, RET, c-KIT and PDGF-R-β. Phase I studies identified the maximum tolerated dose to
[Changes in quality of life and related factors in thyroid cancer patients with radioactive iodine remnant ablation].
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVE
To investigate changes in Quality of life (QOL) and related factors in patients with thyroid cancer undergoing Radioactive Iodine remnant ablation (RAI).
METHODS
Data were collected longitudinally 3 times for 6 months (2 weeks post-surgery, post RAI, 3 months post RAI) in a hospital
Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs)
Efficacy of a Home-Based Exercise Program After Thyroidectomy for Thyroid Cancer Patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
The objective of this study was to determine the effect of a home-based exercise program on fatigue, anxiety, quality of life (QoL), and immune function of thyroid cancer patients taking thyroid hormone replacement after thyroidectomy.
This quasi-experimental study with a non-equivalent control
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
CONCLUSIONS
Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 could be administered safely.Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administer than
L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Hypothyroid patients experience fatigue-related symptoms despite adequate thyroid hormone replacement. Thyroid hormone plays an essential role in carnitine-dependent fatty acid import and oxidation. We investigated the effects of L-carnitine supplementation on fatigue in patients with
Aromatherapy reduces fatigue among women with hypothyroidism: A randomized placebo-controlled clinical trial.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Background This randomized, blinded, placebo-controlled clinical trial identifies the effect of an aromatherapy blend of essential oils on fatigue, which is one of the most commonly unaddressed symptoms of hypothyroidism, by evaluating the effects of daily aromatherapy inhalation. Methods
Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epithelial thyroid tumor growth has been highlighted. Sunitinib is a novel tyrosine kinase inhibitor, approved in 2006 by Food and Drug Administration for the treatment of advanced renal cell and
First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Medullary thyroid cancer (MTC) is a rare disease, the prognosis of advanced and metastatic disease is poor and few therapeutic options are available in this setting. Based on the results of phase II and III studies with sorafenib in differentiated thyroid cancer and the lack of
Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Medullary thyroid cancers (MTCs) are neuroendocrine tumors, which secrete calcitonin and carcinoembryonic antigen, both of which can serve as tumor markers. Extensive and accurate surgical resection is the primary treatment for MTC, whereas the use of external beam radiotherapy is limited. Moreover,
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
